Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in
patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the
follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and
1199.34), who wish to continue treatment with BIBF 1120.